AFMD Affimed N.V.

Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call

Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call

Heidelberg, Germany, March 13, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on March 20, 2018, the Company will release its financial results for the quarter and year ended December 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, March 20, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3160515.

United States:

Germany: +49 (0)69 2222 13420

Netherlands: +31 (0) 20 721 9251

Denmark:

France: +33 (0)1 76 77 22 74

Switzerland: +41 (0)22 567 5729

United Kingdom:+44 (0)330 336 9105

An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at . A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit .

Contact:

Anca Alexandru, Head of Communications, EU IR

Phone: 41

E-Mail: ,

EN
13/03/2018

Underlying

AFMDAffimed N.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Affimed N.V.

 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

Affimed Announces Receipt of Nasdaq Delisting Notice MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 No...

May 14, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capita...

May 13, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantl...

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve e...

April 29, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at th...

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinica...

April 23, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimu...

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed be...

April 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch